{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:18:39Z","timestamp":1789759119472,"version":"4.0.1"},"reference-count":232,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bmc.2019.07.050","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T02:09:57Z","timestamp":1564625397000},"page":"3979-3997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review"],"prefix":"10.1016","volume":"27","author":[{"given":"Jaiprakash","family":"Sangshetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahebaaz K.","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddique","family":"Akber Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Chhajed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohidas","family":"Arote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanand B.","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.07.050_b0005","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1023\/A:1022665331722","article-title":"Synthesis and pharmacological activity of 1-hydroxy-, 1-amino-, and 1-hydrazino-substituted 2,3-dihydro-1H-pyrazolo [1,2-a] pyridazine-5,8-diones and 2,3-dihydro-1H-pyrazolo [1,2-b] phthalazine-5,10-diones","volume":"36","author":"Al-Assar","year":"2002","journal-title":"Pharm Chem J"},{"key":"10.1016\/j.bmc.2019.07.050_b0010","article-title":"Phthalazin-1 (2H)-one","volume":"63","author":"B\u00fcy\u00fckg\u00fcng\u00f6r","year":"2007","journal-title":"Acta Crystallogr Sect E: Struct Rep Online"},{"key":"10.1016\/j.bmc.2019.07.050_b0015","first-page":"1807","article-title":"Analogues: high-affinity \u03b3-aminobutyric acid-a benzodiazepine receptor ligands with r2, r3, and r5-subtype binding selectivity over r1","volume":"7","author":"Carling","year":"2004","journal-title":"Society"},{"key":"10.1016\/j.bmc.2019.07.050_b0020","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.bmcl.2005.03.026","article-title":"Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase","volume":"15","author":"Loh","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0025","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bmcl.2005.10.081","article-title":"Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase","volume":"16","author":"Cockcroft","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0030","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1016\/j.bmc.2004.04.014","article-title":"Synthesis and cytotoxicity of 1-substituted 2-methyl-1H-imidazo [4,5-g] phthalazine-4,9-dione derivatives","volume":"12","author":"Kim","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0035","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.carres.2003.08.016","article-title":"Synthesis and structural characterization of 1-(d-glycosyloxy) phthalazines","volume":"338","author":"Haikal","year":"2003","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0040","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"Novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bioorg.2018.01.034","article-title":"Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer","volume":"77","author":"Almahli","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejmech.2016.07.049","article-title":"Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity","volume":"123","author":"Amin","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1248\/bpb.b15-00656","article-title":"Design and synthesis of new phthalazinone derivatives containing benzyl moiety with anticipated antitumor activity","volume":"39","author":"Marzouk","year":"2016","journal-title":"Biol Pharm Bull Pharm Bull"},{"key":"10.1016\/j.bmc.2019.07.050_b0060","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.bmcl.2016.04.067","article-title":"Development of novel proteasome inhibitors based on phthalazinone scaffold","volume":"26","author":"Yang","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ardp.201500336","article-title":"Synthesis and biological evaluation of new phthalazinone derivatives as anti-inflammatory and anti-proliferative agents","volume":"349","author":"Hameed","year":"2016","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmc.2019.07.050_b0070","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1016\/j.bmcl.2015.10.079","article-title":"Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering","volume":"25","author":"Johannes","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/11070574","article-title":"Synthesis and anticancer activities of novel 1,4-disubstituted phthalazines","volume":"11","author":"Li","year":"2006","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2019.07.050_b0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ejmech.2015.12.015","article-title":"Synthesis, vasorelaxant activity and 2D-QSAR study of some novel pyridazine derivatives","volume":"108","author":"George","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0085","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/jm101346r","article-title":"Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase","volume":"54","author":"Prime","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3998\/ark.5550190.0010.c10","article-title":"Synthesis of chiral N-(2-(1-oxophthalazin-2(1H)-yl) ethanoyl)-\u03b1-amino acid derivatives as antitumor agents","volume":"2009","author":"El Nezhawy","year":"2009","journal-title":"ARKIVOC"},{"key":"10.1016\/j.bmc.2019.07.050_b0095","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1016\/j.jorganchem.2005.07.046","article-title":"Crystal structure, antitumor activities and DNA-binding properties of the La(III) complex with Phthalazin-1(2H)-one prepared by a novel route","volume":"690","author":"Wang","year":"2005","journal-title":"J Organomet Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0100","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.ejmech.2009.10.028","article-title":"Synthesis and anti-inflammatory evaluation of some condensed [4-(3,4-dimethylphenyl)-1 (2H)-oxo-phthalazin-2-yl] acetic acid hydrazide","volume":"45","author":"Hegab","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0105","first-page":"407","article-title":"New cytotoxic and antitumor agents. VII. Derivatives of 1-benzylidenisoindolin-3-one and 5,6-dihydro-8H-isoquinolo (2,3-a) phthalasin-5-one","volume":"32","author":"Fuska","year":"1985","journal-title":"Neoplasma"},{"key":"10.1016\/j.bmc.2019.07.050_b0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/13543784.16.3.367","article-title":"Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours","volume":"16","author":"Scott","year":"2007","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2019.07.050_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cclet.2007.11.018","article-title":"Synthesis and in vitro cytotoxicity of novel 1,4-disubstituted phthalazines","volume":"19","author":"Zhai","year":"2008","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0120","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3390\/12081900","article-title":"Synthesis and in-vitro antitumor activity of 1-[3-(indol-1-yl)prop-1-yn-1-yl]phthalazines and related compounds","volume":"12","author":"Haider","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2019.07.050_b0125","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1021\/acs.jmedchem.8b01689","article-title":"Design and synthesis of 1,2-bis (hydroxymethyl) pyrrolo [2,1-a] phthalazine hybrids as potent anticancer agents that inhibit angiogenesis and induce DNA interstrand cross-links","volume":"62","author":"Chang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0130","first-page":"97","article-title":"Pharmacological activities of various phthalazine and phthalazinone derivatives","volume":"5","author":"Asif","year":"2019","journal-title":"Chem Intl"},{"key":"10.1016\/j.bmc.2019.07.050_b0135","first-page":"463","article-title":"Synthesis and anticonvulsant activity of novel and potent phthalazinone","volume":"11","author":"Grasso","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0223-5234(02)01405-8","article-title":"Pharmacological evaluation of some new 1-substituted-4-hydroxy-phthalazines","volume":"37","author":"Sivakumar","year":"2002","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jjp.28.1","article-title":"Anti-convulsant effect of phthalazino-2,3b-phthalazine-5-(14h), 12 (7h)-dione (L-5418). I. Behavioral effect","volume":"28","author":"Go","year":"1978","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.bmc.2019.07.050_b0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jps.2600700121","article-title":"Formation of thiazoles, thiazines, and thiadiazines from 1-phthalazine thiosemicarbazides as potential anticonvulsants","volume":"70","author":"Soliman","year":"1981","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2019.07.050_b0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1021\/jm950740w","article-title":"Substituted 1,2-dihydrophthalazines: Potent, selective, and noncompetitive inhibitors of the AMPA receptor","volume":"39","author":"Pelletier","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02980038","article-title":"Some pyridazinone and phthalazinone derivatives and their vasodilator activities","volume":"27","author":"Demirayak","year":"2004","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0165","first-page":"3555","article-title":"Pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety","volume":"3","author":"Betti","year":"2003","journal-title":"Society"},{"key":"10.1016\/j.bmc.2019.07.050_b0170","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0968-0896(98)00056-X","article-title":"Analogues as new substrates for 1-adrenoceptor selective antagonists: synthesis, modeling, and binding studies","volume":"6","author":"Montesano","year":"1998","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0175","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1248\/cpb.38.2179","article-title":"Studies on cardiotonic agents. II. Synthesis of novel phthalazine and 1,2,3-benzotriazine derivatives","volume":"38","author":"Nomoto","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2019.07.050_h0180","first-page":"17","article-title":"A brief review on pharmacological effect of some phthalazine derivatives on cardiovascular and kidney functions","volume":"4","author":"Asif","year":"2015","journal-title":"CIB Tech J Pharm Sci"},{"key":"10.1016\/j.bmc.2019.07.050_h0185","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.2174\/092986712800672139","article-title":"Some recent approaches of biologically active substituted pyridazine and phthalazine drugs","volume":"19","author":"Asif","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0185","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tetlet.2014.12.121","article-title":"A comparative synthesis of 6-benzyl-2,3-dihydroimidazo [2,1-a] phthalazine and 2H-7-benzyl-3,4-dihydropyrimido [2,1-a]phthalazine","volume":"56","author":"Munin","year":"2015","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0190","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1021\/jm000558h","article-title":"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives","volume":"44","author":"Ukita","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/jm00081a006","article-title":"Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain","volume":"35","author":"Mylari","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/jm00105a018","article-title":"Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners","volume":"34","author":"Mylari","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ardp.200800016","article-title":"Synthesis and pharmacological evaluation of N-(dimethylamino) ethyl derivatives of benzo-and pyridopyridazinones","volume":"342","author":"Pakulska","year":"2009","journal-title":"Arch der Pharm An Int J Pharm Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0210","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/jm0110338","article-title":"Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones","volume":"45","author":"Van der Mey","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0215","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1021\/jm00042a008","article-title":"Cyclic benzamides as mixed dopamine D2\/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents","volume":"37","author":"Norman","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0220","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1016\/j.ejmech.2010.08.005","article-title":"Synthesis and antimicrobial activity of 2-substituted [4-(1,3,4-oxadiazol-2-yl methyl)]phthalazin-1(2H)-one derivatives","volume":"45","author":"Sridhara","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0225","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1021\/jm00376a013","article-title":"7-(Ethoxycarbonyl)-6,8-dimethyl-2-phenyl-1 (2H)-phthalazinone derivatives: synthesis and inhibitory effects on platelet aggregation","volume":"27","author":"Sugimoto","year":"1984","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2012.02.051","article-title":"Synthesis, vasorelaxant activity, and molecular modeling study of some new phthalazine derivatives","volume":"52","author":"Awadallah","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0235","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.ejmech.2009.10.028","article-title":"Synthesis and anti-inflammatory evaluation of some condensed [4-(3,4-dimethylphenyl)-1(2H)-oxo-phthalazin-2-yl]acetic acid hydrazide","volume":"45","author":"Abdalla","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ardp.200200719","article-title":"Synthesis of new 2-[1(2H)-phthalazinon-2-yl]-acetamide and 3-[1(2H)-phthalazinon-2-yl]-propanamide derivatives as antinociceptive and anti-inflammatory agents","volume":"337","author":"Dogruer","year":"2004","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmc.2019.07.050_b0245","article-title":"ChemInform abstract: the synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors. Part 1","volume":"31","author":"Napoletano","year":"2010","journal-title":"ChemInform"},{"key":"10.1016\/j.bmc.2019.07.050_b0250","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0960-894X(03)00493-1","article-title":"Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors","volume":"13","author":"Chakraborti","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0255","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/jm010837k","article-title":"Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues","volume":"44","author":"Van der Mey","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0260","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.tetlet.2003.12.070","article-title":"Synthesis of benzo [4,5] imidazo [2,1-a] phthalazines","volume":"45","author":"Shubin","year":"2004","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0265","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/jm970105l","article-title":"Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors","volume":"40","author":"Dal Piaz","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0270","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/S0960-894X(01)00562-5","article-title":"Anti-Trypanosoma activity of some natural stilbenoids and synthetic related heterocyclic compounds","volume":"11","author":"del Olmo","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0275","doi-asserted-by":"crossref","first-page":"1800299","DOI":"10.1002\/ardp.201800299","article-title":"Antileismanial activity, mechanism of action study and molecular docking of 1,4-bis (substituted benzalhydrazino) phthalazines","volume":"352","author":"Romero","year":"2019","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2019.07.050_b0280","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/CCO.0000000000000091","article-title":"Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma","volume":"26","author":"Vormoor","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bmc.2019.07.050_b0285","doi-asserted-by":"crossref","unstructured":"Bryant HE, Helleday T. Poly (ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. 2004;32:959-961. doi: 10.1042\/BST0320959.","DOI":"10.1042\/BST0320959"},{"key":"10.1016\/j.bmc.2019.07.050_b0290","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. [erratum appears in Nature. 2007 May 17;447(7142): 346]","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.07.050_b0295","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Martin","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.07.050_b0300","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1021\/jm800582j","article-title":"Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease","volume":"51","author":"Kodimuthali","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0960-894X(00)00587-4","article-title":"Phthalazine PDE4 inhibitors. Part 2: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives","volume":"11","author":"Napoletano","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0310","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1081\/SCC-120015568","article-title":"Mild and efficient synthesis of phthalazine-1,4-diones using PTSA in the solid state","volume":"33","author":"Mogilaiah","year":"2003","journal-title":"Synth Commun"},{"key":"10.1016\/j.bmc.2019.07.050_b0315","first-page":"132","article-title":"Recent developments in chemistry of phthalazines","volume":"1","author":"El-Azm","year":"2015","journal-title":"Org Chem Curr Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0320","doi-asserted-by":"crossref","first-page":"1700240","DOI":"10.1002\/ardp.201700240","article-title":"Design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR-2 inhibitors","volume":"350","author":"El-Helby","year":"2017","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2019.07.050_b0325","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.ejmech.2010.05.016","article-title":"Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives","volume":"45","author":"Zhang","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0330","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1002\/jhet.2985","article-title":"Synthesis of novel phthalazine derivatives as potential anticancer and antioxidant agents based on 1-chloro-4-(4-phenoxyphenyl) phthalazine","volume":"54","author":"Behalo","year":"2017","journal-title":"J Heterocycl Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0335","first-page":"1","article-title":"A mixed-ligand quinazoline-based Ni (II) Schiff base complex: synthesis, characterization, crystal structure, antimicrobial investigation and catalytic activity for the synthesis of 2H-indazolo [2,1-b] phthalazine-triones","volume":"32","author":"Khajoee","year":"2017","journal-title":"Appl Organomet Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0340","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejmech.2016.02.029","article-title":"Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives","volume":"113","author":"Eldehna","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0345","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2174\/1385272821666170221150901","article-title":"Recent advances in the synthesis of biologically active cinnoline, phthalazine and quinoxaline derivatives","volume":"21","author":"Taek Han","year":"2017","journal-title":"Curr Org Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0350","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ejoc.201800159","article-title":"Palladium-catalyzed acylation reactions: a one-pot diversified synthesis of phthalazines, phthalazinones and benzoxazinones","volume":"19","author":"Suchand","year":"2018","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0355","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.tetlet.2005.07.018","article-title":"Microwave-assisted cyclocondensation of hydrazine derivatives with alkyl dihalides or ditosylates in aqueous media: syntheses of pyrazole, pyrazolidine and phthalazine derivatives","volume":"46","author":"Ju","year":"2005","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0360","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1039\/C7CS00082K","article-title":"Benzodiazines: recent synthetic advances","volume":"46","author":"Mathew","year":"2017","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0365","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.1021\/acs.joc.8b00661","article-title":"Ligand redox-controlled tandem synthesis of azines from aromatic alcohols and hydrazine in air: one-pot synthesis of phthalazine","volume":"83","author":"Chakraborty","year":"2018","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0370","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/ol301167q","article-title":"One-pot synthesis of phthalazines and pyridazino-aromatics: a novel strategy for substituted naphthalenes","volume":"14","author":"Kessler","year":"2012","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0375","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1515\/hc-2012-0079","article-title":"Efficient synthesis of selected phthalazine derivatives","volume":"18","author":"Bunce","year":"2012","journal-title":"Heterocycl Commun"},{"key":"10.1016\/j.bmc.2019.07.050_b0380","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.tetlet.2013.05.006","article-title":"Microwave assisted palladium-catalyzed synthesis of phthalazinones and pyridopyridazinones","volume":"54","author":"Rao","year":"2013","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0385","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2018.10.047","article-title":"Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry","volume":"161","author":"Teran","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0390","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1055\/s-2001-18056","article-title":"Synthetic strategies based on directed ortho-metalation: synthesis of 4-methyl-2H-phthalazin-1-ones","volume":"14","author":"Epsztajn","year":"2001","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2019.07.050_b0395","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-1998-2036","article-title":"A new and efficient synthesis of phthalazin-1(2H)-ones","volume":"3","author":"Bernard","year":"1998","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2019.07.050_b0400","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1021\/jm00077a009","article-title":"Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones","volume":"36","author":"Yamaguchi","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0405","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1021\/jo034510y","article-title":"Aluminum chloride-induced heteroarylation of arenes and heteroarenes. 2. A new synthesis of 4-substituted phthalazin-1(2H)-ones","volume":"68","author":"Pal","year":"2003","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0410","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/A:1007152927167","article-title":"Antioxidative and anti-tumour activities of solid quercetin metal(II) complexes","volume":"26","author":"Zhou","year":"2001","journal-title":"Transit Met Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0415","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/cr60277a001","article-title":"Metals, ligands, and cancer","volume":"72","author":"Williams","year":"1972","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0420","first-page":"7","article-title":"Cancer statistics, 2018 CA: a cancer","volume":"68","author":"Siegel","year":"2017","journal-title":"J Clin"},{"key":"10.1016\/j.bmc.2019.07.050_b0425","first-page":"30","article-title":"Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening","volume":"65","author":"Smith","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2019.07.050_b0430","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2013an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.bmc.2019.07.050_b0435","unstructured":"World helath organization. International Organization."},{"key":"10.1016\/j.bmc.2019.07.050_b0440","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.279.5356.1534","article-title":"A model for the mechanism of human topoisomerase I","volume":"279","author":"Stewart","year":"1998","journal-title":"Science (80-)"},{"key":"10.1016\/j.bmc.2019.07.050_b0445","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","article-title":"Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I","volume":"260","author":"Hsiang","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0450","series-title":"Progress in Nucleic Acid Research and Molecular Biology","first-page":"111","article-title":"Domains of human topoisomerase I and associated functions","author":"Champoux","year":"2008"},{"key":"10.1016\/j.bmc.2019.07.050_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4781(95)00029-G","article-title":"Eukaryotic DNA topoisomerases I","volume":"1262","author":"Gupta","year":"1995","journal-title":"BBA \u2013 Gene Struct Expr"},{"key":"10.1016\/j.bmc.2019.07.050_b0460","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.bi.65.070196.003223","article-title":"DNA topoisomerases","volume":"65","author":"Wang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2019.07.050_b0465","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2019.07.050_b0470","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature03395","article-title":"Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB","volume":"434","author":"Koster","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.07.050_b0475","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00003495-199856040-00017","article-title":"Topotecan","volume":"56","author":"Brogden","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2019.07.050_b0480","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0304-3835(97)00428-X","article-title":"Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice","volume":"124","author":"Choi","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0485","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1073\/pnas.92.9.3726","article-title":"Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania","volume":"92","author":"Bodley","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2019.07.050_b0490","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1158\/0008-5472.CAN-07-0938","article-title":"Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance","volume":"67","author":"Antony","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0495","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/bjc.1998.360","article-title":"Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation","volume":"77","author":"Sorensen","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2019.07.050_b0500","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41419-018-0981-3","article-title":"PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin","volume":"9","author":"Mouly","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2019.07.050_b0505","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1016\/j.ejmech.2010.05.048","article-title":"Synthesis and antiproliferative activity of indolizinophthalazine-5,12-dione derivatives, DNA topoisomerase IB inhibitors","volume":"45","author":"Shen","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0510","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2019.07.050_b0515","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0520","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1042\/BST20130187","article-title":"PARP inhibitors for anticancer therapy","volume":"42","author":"Curtin","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2019.07.050_b0525","first-page":"55","article-title":"Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer","volume":"24","author":"Comen","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.bmc.2019.07.050_b0530","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2019.07.050_b0535","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2019.07.050_b0540","series-title":"Specific Inhibitors of Poly(ADP-Ribose) Synthetase. ADP-ribosylation reactions","first-page":"343","author":"Banasik","year":"1992"},{"key":"10.1016\/j.bmc.2019.07.050_b0545","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13053-014-0024-8","article-title":"PARP inhibitors","volume":"13","author":"Anwar","year":"2015","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.bmc.2019.07.050_b0550","doi-asserted-by":"crossref","first-page":"S714","DOI":"10.1016\/j.ijrobp.2008.06.550","article-title":"In vitro and in vivo radiosensitization of glioblastoma multiforme by poly (ADP-ribose) polymerase inhibitor, GPI 21016","volume":"72","author":"Russo","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.bmc.2019.07.050_b0555","unstructured":"US national library of medicine for clinical trials,. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01945775."},{"key":"10.1016\/j.bmc.2019.07.050_b0560","unstructured":"US national library of medicine for clinical trials, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02034916?term=BMN+673."},{"key":"10.1016\/j.bmc.2019.07.050_b0565","unstructured":"US national library of medicine for clinical trials, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01945775."},{"key":"10.1016\/j.bmc.2019.07.050_b0570","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.onc.1201065","article-title":"A putative serine\/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines","volume":"14","author":"Sen","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2019.07.050_b0575","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc1502","article-title":"Aurora-kinase inhibitors as anticancer agents","volume":"4","author":"Keen","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2019.07.050_b0580","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.pharmthera.2006.02.006","article-title":"Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis","volume":"111","author":"Li","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2019.07.050_b0585","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal growth factor receptor in pancreatic cancer","volume":"3","author":"Oliveira-Cunha","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2019.07.050_b0590","first-page":"890","article-title":"Epidermal growth factor receptor family and its role in cancer progression","volume":"88","author":"Nair","year":"2005","journal-title":"Curr Sci"},{"key":"10.1016\/j.bmc.2019.07.050_b0595","doi-asserted-by":"crossref","first-page":"12424","DOI":"10.1038\/s41598-018-30804-z","article-title":"The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR\/STAT3-mediated pathway","volume":"8","author":"Ta","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2019.07.050_b0600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/107327480200902S05","article-title":"Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers","volume":"9","author":"Lee","year":"2002","journal-title":"Cancer Control"},{"key":"10.1016\/j.bmc.2019.07.050_b0605","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543776.15.6.647","article-title":"VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures","volume":"15","author":"Dumas","year":"2005","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2019.07.050_b0610","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bioorg.2018.12.039","article-title":"Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma","volume":"1","author":"Boraei","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0615","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cr0502504","article-title":"20S proteasome and its inhibitors: crystallographic knowledge for drug development","volume":"107","author":"Borissenko","year":"2007","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0620","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1574-6976.2011.00290.x","article-title":"Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria","volume":"36","author":"Nikaido","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0625","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/14656566.4.2.165","article-title":"Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection","volume":"4","author":"Khare","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmc.2019.07.050_b0630","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jac\/48.3.391","article-title":"Characterization of paired mucoid\/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting","volume":"48","author":"Ciofu","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2019.07.050_b0635","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.micro.57.030502.090720","article-title":"Bacterial biofilms: an emerging link to disease pathogenesis","volume":"57","author":"Parsek","year":"2003","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.bmc.2019.07.050_b0640","first-page":"1318","article-title":"Bacterial biofilms: a common cause of persistent","volume":"64","author":"Costerton","year":"1999","journal-title":"Infect Sci"},{"key":"10.1016\/j.bmc.2019.07.050_b0645","doi-asserted-by":"crossref","DOI":"10.1002\/chin.201023258","article-title":"ChemInform abstract: quorum sensing and bacterial biofilms","volume":"41","author":"Dickschat","year":"2010","journal-title":"ChemInform"},{"key":"10.1016\/j.bmc.2019.07.050_b0650","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1099\/mic.0.033290-0","article-title":"Genetic determinants of Pseudomonas aeruginosa biofilm establishment Printed in Great Britain","volume":"156","author":"Mu","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.bmc.2019.07.050_b0655","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1086\/502581","article-title":"Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance","volume":"26","author":"Morgan","year":"2006","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.bmc.2019.07.050_b0660","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/MMBR.00045-10","article-title":"Regulatory circuitry governing fungal development, drug resistance, and disease","volume":"75","author":"Shapiro","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0665","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bmcl.2016.02.057","article-title":"Novel amalgamation of phthalazine\u2013quinolines as biofilm inhibitors: one-pot synthesis, biological evaluation and in silico ADME prediction with favorable metabolic fate","volume":"26","author":"Zaheer","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0670","doi-asserted-by":"crossref","first-page":"86695","DOI":"10.1039\/C6RA19902J","article-title":"Copper(II) complexes with aromatic nitrogen-containing heterocycles as effective inhibitors of quorum sensing activity in Pseudomonas aeruginosa","volume":"6","author":"Gli\u0161i\u0107","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2019.07.050_b0675","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"The task force for the management ofarterial hypertension of the european society of hypertension (esh) and of the european society of cardiology","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.bmc.2019.07.050_b0680","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/eurheartj\/eht465","article-title":"State-of-the-art treatment of hypertension: established and new drugs","volume":"35","author":"Burnier","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bmc.2019.07.050_b0685","first-page":"157","article-title":"Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial","volume":"128","author":"Vigil-De Gracia","year":"2006","journal-title":"Obstet Gynecol Int J"},{"key":"10.1016\/j.bmc.2019.07.050_b0690","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1248\/cpb.36.2669","article-title":"Studies on vasoactive heterocyclic compounds. Preparation and evaluation of the hypotensive and antiaggregating activities of phthalazinol nitrates","volume":"36","author":"Ito","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2019.07.050_b0695","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1016\/j.bmcl.2006.02.003","article-title":"Vasorelaxant activity of phthalazinones and related compounds","volume":"16","author":"del Olmo","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0700","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/jm00156a011","article-title":"Synthesis, saludiuretic, and antihypertensive activity of 6,7-disubstituted 1 (2H)-and 3,4-dihydro-1 (2H)-phthalazinones","volume":"29","author":"Cherkez","year":"1986","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0705","article-title":"Cheminform abstract: identification of two new metabolites of hydralazine from human urine","volume":"5","author":"Zak","year":"2016","journal-title":"Chem Inf"},{"key":"10.1016\/j.bmc.2019.07.050_b0710","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ejmech.2010.11.045","article-title":"Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as \u03b11-adrenoreceptor antagonists","volume":"46","author":"Abou-Seri","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0715","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1016\/j.ejmech.2009.04.028","article-title":"Design, synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxy-propyl]-3,3-diphenylpyrrolidin-2-one derivatives with antiarrhythmic, antihypertensive, and \u03b1-adrenolytic activity","volume":"44","author":"Kulig","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0720","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/cpb.43.332","article-title":"Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. VI. Indazole derivatives","volume":"43","author":"Yamaguchi","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2019.07.050_b0725","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00044-012-0099-6","article-title":"4-Substituted phthalazines and phthalazinones: synthesis, characterization and \u03b2-adrenergic blocking activity","volume":"22","author":"Abouzid","year":"2013","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0730","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejmech.2013.11.037","volume":"73","author":"Bakale","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0735","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1016\/j.ejmech.2009.04.044","article-title":"Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives","volume":"44","author":"K\u00fcmmerle","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0740","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4330\/wjc.v7.i12.889","article-title":"Thrombus aspiration during primary percutaneous coronary intervention for acute myocardial infarction: a review of clinical evidence and guidelines","volume":"7","author":"Mahmood","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.bmc.2019.07.050_b0745","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1524-6175.2004.03508.x","article-title":"Systolic hypertension in the elderly: pushing the frontiers of therapy\u2014a suggested new approach","volume":"6","author":"Stokes","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.bmc.2019.07.050_b0750","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fphys.2014.00294","article-title":"Platelets and their chemokines in atherosclerosis-clinical applications","volume":"5","author":"von Hundelshausen","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.bmc.2019.07.050_b0755","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/092986712803414240","article-title":"New perspectives in antiplatelet therapy","volume":"19","author":"Tello-Montoliu","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0760","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1248\/cpb.28.2770","article-title":"Studies on antiatherosclerotic agents. IX. Synthesis of 7-ethoxycarbonyl-4-hydroxymethyl-6,8-dimethyl-1(2H)-phthalazinone (EG 626)","volume":"28","author":"Ishikawa","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2019.07.050_b0765","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1248\/cpb.33.2809","article-title":"Synthesis and inhibitory effect on platelet aggregation of 2-phenyl-1(2H)-phthalazinone derivatives","volume":"33","author":"Sugimoto","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2019.07.050_b0770","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1248\/cpb.39.795","article-title":"Studies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compounds","volume":"39","author":"Eguchi","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2019.07.050_b0775","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00044-017-1879-9","article-title":"Synthesis and vasorelaxant and antiplatelet activities of a new series of (4-Benzylphthalazin-1-ylamino) alcohol derivatives","volume":"26","author":"Mun\u00edn","year":"2017","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0780","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1467-789x.2000.00013.x","article-title":"Redefining type 2 diabetes: \u2018diabesity\u2019 or \u2018obesity dependent diabetes mellitus\u2019?","volume":"1","author":"Astrup","year":"2001","journal-title":"Obes Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0785","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.07.050_b0790","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2796.2000.00625.x","article-title":"Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?","volume":"247","author":"Zimmet","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.bmc.2019.07.050_b0795","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.bmc.2019.07.050_b0800","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO;2-7","article-title":"Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches","volume":"19","author":"Costantino","year":"1999","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0805","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1021\/jm981107o","article-title":"Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors","volume":"42","author":"Costantino","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0810","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1146\/annurev.pa.25.040185.003355","article-title":"The pharmacology of aldose reductase inhibitors","volume":"25","author":"Kador","year":"2002","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2019.07.050_b0815","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1021\/jm00145a001","article-title":"Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications","volume":"28","author":"Kador","year":"1985","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0820","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0891-6632(89)90003-2","article-title":"Aldose reductase in the etiology of diabetic complications: I. Introduction","volume":"3","author":"Harrison","year":"1989","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.bmc.2019.07.050_b0825","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0891-6632(89)90015-9","article-title":"Aldose reductase in the etiology of diabetic complications: 2. Nephropathy","volume":"3","author":"Stribling","year":"2004","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.bmc.2019.07.050_b0830","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0891-6632(89)90036-6","article-title":"Aldose reductase in the etiology of diabetic complications 3. Neuropathy","volume":"3","author":"Stribling","year":"1989","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.bmc.2019.07.050_b0835","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0891-6632(90)90048-A","article-title":"Aldose reductase in the etiology of diabetic complications: 4 Retinopathy","volume":"4","author":"Stribling","year":"1989","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.bmc.2019.07.050_b0840","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/092986709787458362","article-title":"Aldose reductase enzyme and its implication to major health problems of the 21(st) century","volume":"16","author":"Alexiou","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0845","article-title":"Diabetes mellitus: complications and therapeutics","volume":"12","author":"Tripathi","year":"2006","journal-title":"Med Sci Monit."},{"key":"10.1016\/j.bmc.2019.07.050_b0850","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diabres.2006.04.017","article-title":"Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy","volume":"74","author":"Harada","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bmc.2019.07.050_b0855","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.2337\/diabetes.53.11.2910","article-title":"Activation of nulcear factor-\u03baB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase","volume":"53","author":"Ramana","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2019.07.050_b0860","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1046\/j.1523-1755.2000.07702.x","article-title":"Aldose reductase and the role of the polyol pathway in diabetic nephropathy","volume":"58","author":"Dunlop","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.bmc.2019.07.050_b0865","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0026-0495(85)90223-9","article-title":"Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat","volume":"34","author":"Stribling","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.bmc.2019.07.050_b0870","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1021\/jm00090a002","article-title":"Orally active aldose reductase inhibitors: indazole acetic, oxopyridazine acetic, and oxopyridopyridazine acetic acid derivatives","volume":"35","author":"Mylari","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0875","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1381612802666220920215821","article-title":"The glitazone family of antidiabetic agents","volume":"2","author":"Hulin","year":"1996","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmc.2019.07.050_b0880","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/jm950395a","article-title":"The Structure\u2013Activity relationship between peroxisome proliferator-activated receptor \u03b3 agonism and the antihyperglycemic activity of thiazolidinediones","volume":"39","author":"Willson","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0885","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0890","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2019.07.050_b0895","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0223-5234(01)01257-0","article-title":"Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents","volume":"36","author":"Madhavan","year":"2001","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0900","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1016\/j.bmcl.2013.07.067","article-title":"Discovery of thiazolyl-phthalazinone acetamides as potent glucose uptake activators via high-throughput screening","volume":"23","author":"Agrawal","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0905","first-page":"195","article-title":"XXXII. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edward Stone, of Chipping-Norton in Oxfordshire","volume":"53","author":"Stone","year":"2006","journal-title":"Philos Trans R Soc London"},{"key":"10.1016\/j.bmc.2019.07.050_b0910","first-page":"573","article-title":"The fight against rheumatism: from willow bark to COX-1 sparing drugs","volume":"51","author":"Vane","year":"2000","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.bmc.2019.07.050_b0915","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1016\/S0021-9258(18)97174-7","article-title":"Biosynthesis of prostaglandins from arachidonic acid in guinea pig lung prostaglandins and related factors 38","volume":"240","author":"\u00c4ngg\u00e5rd","year":"1965","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0920","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"key":"10.1016\/j.bmc.2019.07.050_b0925","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1471-4159.1982.tb05355.x","article-title":"Evidence for two distinct forms of fatty acid cyclooxygenase in brain","volume":"38","author":"Lysz","year":"1982","journal-title":"J Neurochem"},{"key":"10.1016\/j.bmc.2019.07.050_b0930","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/S0021-9258(18)53294-4","article-title":"Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin","volume":"268","author":"Meade","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0935","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000136674","article-title":"The effect of prostaglandin E1 on central cholinergic mechanisms","volume":"15","author":"Bodzenta","year":"1977","journal-title":"Pharmacology"},{"key":"10.1016\/j.bmc.2019.07.050_b0940","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ardp.201300056","article-title":"Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents","volume":"346","author":"Yaseen","year":"2013","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmc.2019.07.050_b0945","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bmcl.2016.02.008","article-title":"Synthesis and anti-inflammatory activity evaluation of a novel series of 6-phenoxy-[1,2,4] triazolo [3,4-a] phthalazine-3-carboxamide derivatives","volume":"26","author":"Liu","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.07.050_b0950","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1528-1167.2005.01605.x","article-title":"Psychological distress, comorbidities, and health behaviors among US adults with seizures: results from the 2002 National Health Interview Survey","volume":"46","author":"Strine","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.bmc.2019.07.050_b0955","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1528-1167.2009.02234.x","article-title":"Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy","volume":"50","author":"Penovich","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.bmc.2019.07.050_b0960","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00706-011-0462-1","article-title":"Exploration on structure and anticonvulsant activity of transition metal complexes derived from an \u201cend-off\u201d compartmental bis-quinoxaline derivative with phthalazinyl-diazine as endogenous bridge","volume":"142","author":"Budagumpi","year":"2011","journal-title":"Monatsh Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0965","first-page":"127","article-title":"Synthesis and anticonvulsant activity 6-alkoxy-[1,2,4] triazolo [3,4-a] phthalazin-3 (2H)-ones","volume":"23","author":"Cheng-Xi","year":"2011","journal-title":"Asian J Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0970","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/14756366.2012.684052","article-title":"Synthesis and anticonvulsant activity evaluation of 6-substituted-[1,2,4] triazolo [3,4-a](tetrazolo [5,1-a]) phthalazine derivatives","volume":"28","author":"Bian","year":"2013","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b0975","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1055\/s-0032-1323758","article-title":"Some novel anticonvulsant agents derived from phthalazinedione","volume":"62","author":"Zayed","year":"2012","journal-title":"Arzneimittel-Forschung\/Drug Res"},{"key":"10.1016\/j.bmc.2019.07.050_b0980","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1528-1167.2008.01997.x","article-title":"Long-term seizure outcome of surgery versus no surgery for drug-resistant partial epilepsy: a review of controlled studies","volume":"50","author":"Schmidt","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.bmc.2019.07.050_b0985","first-page":"531","article-title":"The new generation of antiepileptic drugs: advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2019.07.050_b0990","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/(SICI)1098-1128(199711)17:6<537::AID-MED3>3.0.CO;2-2","article-title":"Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents","volume":"17","author":"Lin","year":"1997","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2019.07.050_b0995","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11030-018-9871-y","article-title":"Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking","volume":"23","author":"El-Helby","year":"2019","journal-title":"Mol Diversity"},{"key":"10.1016\/j.bmc.2019.07.050_b1000","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejmech.2017.07.072","article-title":"New racemic annulated pyrazolo [1,2-b] phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease","volume":"139","author":"Jalili-baleh","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103004","article-title":"Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors","volume":"89","author":"T\u00fcrke\u015f","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2019.07.050_b1010","unstructured":"Jiang Y, Yuan Z, Gao C, Chen S. Phthalazone hydroxamic acid derivative as well as preparation method and application thereof. 2017. CN 2017106946792 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1015","unstructured":"Liu G, Yu H, Ren Y, Du J, Yang D, Li X. Phthalazinone derivative, and preparation method and use thereof. 2017. WO 2017101796 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1020","unstructured":"Srivastava BK, Desai RC, Patel PR. Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1. 2014. WO 2014102817 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1025","unstructured":"Wang Y, Zhang C, Ji J, Zhang J, Wang X, Zhang W. Novel phthalazinone derivatives and uses thereof . CN 102898377 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1030","unstructured":"Deng B, Li X, Wang B, et al. Phthalazinone derivative, its preparation method and application in medicament. 2012. CN 102372706 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1035","unstructured":"Deng B, Zhang X, Li X, Zhu Y, Yang B. Phthalazinone derivative and its preparation method and use in medicine. 2012. CN 102372698 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1040","unstructured":"Tang P, Li X, Wang B, et al. Phthalazinone derivative, and preparation method and pharmaceutical use thereof. 2012. WO 2012019426 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1045","unstructured":"N. Hawkins N. Phthalazinone compound as parp inhibitor. 2011. WO 2011007145 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1050","unstructured":"Menear KA, Javaid MH, Gomez S, et al. Phthalazinone derivatives. 2009.WO 2009093032 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1055","unstructured":"Javaid MH, Menear KA, Martin NMB, Smith GCM, Rudge DA, Roberts CA, Phthalazinone derivatives as inhibitors of parp-1. 2009. WO 2009004356 A1.A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1060","unstructured":"Gandhi VB, Giranda VL, Gong JP, Penning TD, Zhu G. Inhibitors of poly(adp-ribose)polymerase. 2008. US 20080269234 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1065","unstructured":"Martin NMB, Smith GC, Jackson SP, et al. Phthalazinone derivatives. 2005. US Pat, 20050059663 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1070","unstructured":"Javaid MH, Menear KA, Martin NMB, et al. 4-Heteroarymethyl substituted phthalazinone derivatives. 2007. WO 2007045877 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1075","unstructured":"Kang JH, Lee HS, Lee YS, Park JT, Jung JA, Song DG, Phthalazinone derivatives. 2017. KR 2017037116 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1080","unstructured":"Javaid MH, Menear KA, Martin NMB, Phthalazinone derivatives. 2009. WO 2009034326 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1085","unstructured":"Menear KA, Hummersone MG, Gomez S, Javaid MH, Martin NMB. Phthalazinone derivatives and their use as medicament to treat cancer. 2008. WO 2008\/122810 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1090","unstructured":"Menear KA, Hummersone MG, Gomez S, Javaid MH, Martin NMB, Kerrigan F. Phthalazinone derivatives. 2008. WO 2008114023 A2."},{"key":"10.1016\/j.bmc.2019.07.050_b1095","unstructured":"Martin NMB, Smith GC, Jackson SP, et al. Phthalazinone derivatives. 2004. WO 2004080976 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1100","unstructured":"Martin NMB, Smith GC, Eversley PJ, et al. Phthalazinone derivatives. 2003. WO 2003093261 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1105","unstructured":"Vu CB. Phthalazinone and related analogs as sirtuin modulators. 2013. US 20130190309 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1110","unstructured":"Vu CB, Phthalazinone and related analogs as sirtuin modulators. 2010. WO 2010077947 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1115","unstructured":"Cole BM. Phthalazinone compounds and methods for the treatment of cystic fibrosis. US 20140274933 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1120","unstructured":"Gharat LA, Banerjee A, Khairatkar-Joshi N, Kattige VG. Phtalazinone derivatives as mpegs -1 inhibitors. 2013. WO 2013072825 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1125","unstructured":"Li C, Cao Y, Shen W. Substituted 2,3-phthalazinone compounds and application thereof. 2012. CN 102485721 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1130","unstructured":"Li C, Cao Y, Shen W. Substituted 2,3-phthalazinone compounds and use thereof. 2012. WO 2012072033 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1135","unstructured":"Zhu G, Gandhi VB, Shoemaker AR, Penning TD, Gong J. Phthalazin-(2h)-one inhibitors of kinases. 2011. WO 2011130478 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1140","unstructured":"Zembower DE, Singh J, Mishra RK. Small molecule modulators of cytokine activity. 2006. WO 2006036981 A2."},{"key":"10.1016\/j.bmc.2019.07.050_b1145","unstructured":"Boyd E, Brookfield F, Georges G, et al. Novel phthalazinone derivatives, as aurora-a kinase inhibitors. 2006. WO 2006032518 A1."},{"key":"10.1016\/j.bmc.2019.07.050_b1150","unstructured":"Okuyama S, Takeuchi A, Takihiro 4-(3-(4-Morpholinobutylamino)phenyl)-2H-phthalazin-1-one methane sulfonate monohydrate and method for producing the same. 2003. JP Pat. 2002030073 A."},{"key":"10.1016\/j.bmc.2019.07.050_b1155","unstructured":"Vidya BL, Braj BL, Sekar RA, Rajagopalan R, Chakrabarti R. Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them. 1998. US 5801173 A."}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619310193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619310193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:03:26Z","timestamp":1760835806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619310193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":232,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0968089619310193"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.07.050","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.07.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}